Rmc-4630 (Not yet branded)
Other Medications
Description
RMC-4630 is a SHP2 inhibitor being developed for treatment of KRAS-mutated colorectal cancers and other solid tumors. This compound targets the SHP2 phosphatase, which plays a critical role in oncogenic signaling pathways downstream of mutated KRAS proteins. In colorectal cancer, RMC-4630 is being evaluated in combination with MEK inhibitors like LY3214996 to provide dual pathway blockade in tumors harboring KRAS mutations.
Mechanism of Action
RMC-4630 selectively inhibits SHP2 (Src homology region 2 domain-containing phosphatase-2), an essential mediator of RAS/MAPK signaling. By blocking SHP2 activity, the drug disrupts the transmission of growth signals from mutated KRAS proteins, potentially leading to tumor growth inhibition. The combination approach with MEK inhibitors aims to overcome resistance mechanisms and enhance therapeutic efficacy.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.